DelveInsight’s “HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the HER2+ Gastric Cancer, historical and forecasted epidemiology as well as the HER2+ Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of HER2+ Gastric Cancer, offering comprehensive insights into the HER2+ Gastric Cancer revenue trends, prevalence, and treatment landscape. The report delves into key HER2+ Gastric Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging HER2+ Gastric Cancer therapies. Additionally, we cover the landscape of HER2+ Gastric Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of HER2+ Gastric Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the HER2+ Gastric Cancer space.

To Know in detail about the HER2+ Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HER2+ Gastric Cancer Market Forecast

Some of the key facts of the HER2+ Gastric Cancer Market Report:

• The HER2+ gastric cancer market in the 7MM is anticipated to increase from USD 702 million in 2025, growing at a CAGR of 14.20% and reaching approximately USD 2,318 million by 2034.

• In November 2025, DPTX3186, a first-in-class oral condensate-modulating agent (c-mod), has received FDA fast track designation for the treatment of gastric cancer.

• In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as a first-line treatment for GEA in 2026. The company also plans to expand its market strategy for zanidatamab during the same year.

• In February 2025, AstraZeneca expects the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial—targeting metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA—to provide a data readout in 2026.

• In February 2025, AstraZeneca plans to initiate first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer and GEJ adenocarcinoma in Q1 2025, with data expected to become available post-2026.

• AstraZeneca expects data from the DESTINY-Gastric04 (NCT04704934) trial—evaluating HER2+ gastric cancer or GEJ adenocarcinoma patients who have progressed following a trastuzumab-containing regimen and have not received further systemic therapy—to be available in H2 2025.

• In January 2025, ALX Oncology reported positive updated results from the ASPEN-06 Phase II trial at the 2025 ASCO Gastrointestinal Cancers Symposium, showing that their investigational CD47-blocker, evorpacept, delivers a durable clinical response and has a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric or GEJ cancer.

• In 2024, the HER2+ gastric cancer market was largest in the US among the 7MM, valued at approximately USD 300 million, and is projected to grow further by 2034.

• In 2024, Trastuzumab ± Chemotherapy generated the highest revenue among existing therapies for HER2+ gastric cancer in the United States, amounting to approximately USD 140 million.

• Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) is currently the only approved treatment for advanced or metastatic HER2+ gastric cancer in the second-line (2L) setting, having received accelerated approval in January 2021. For first-line (1L) therapy, ENHERTU is joined by KEYTRUDA (pembrolizumab) and HERCEPTIN (trastuzumab) as approved treatment options for HER2+ gastric cancer.

• Key HER2+ Gastric Cancer Companies: Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharmaceuticals, BeiGene, and Zymeworks, Shanghai Henlius Biotech and AbClon, AstraZeneca, ALX Oncology, Pfizer, Bayer, Artiva Biotherapeutics and GC Cell, KLUS Pharma, Shanghai Miracogen, Enliven Therapeutics, Ambrx and NovoCodex, Mersana Therapeutics and GSK, SystImmune, and others

• Key HER2+ Gastric Cancer Therapies: KEYTRUDA (pembrolizumab), ENHERTU (trastuzumab deruxtecan), ZIIHERA (zanidatamab), HLX22 (AC101), Rilvegostomig, Evorpacept (ALX148), TUKYSA (tucatinib), AY2927088, AB-201 (GCC2003,HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others

• The HER2+ Gastric Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage HER2+ Gastric Cancer pipeline products will significantly revolutionize the HER2+ Gastric Cancer market dynamics.

• In the United States, approximately 15% of patients with advanced gastric cancer and 30% of those with advanced gastroesophageal junction (GEJ) cancer exhibit HER2-positive tumors.

• In 2024, the United States recorded approximately 6,650 new cases of HER2+ gastric cancer, while Japan reported the highest number of cases, totaling around 27,000.

HER2+ Gastric Cancer Overview

HER2+ Gastric Cancer is a subtype of gastric (stomach) cancer characterized by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is involved in cell growth and division, and its abnormal activation can drive tumor progression. Patients with HER2+ gastric cancer often have more aggressive disease, but the presence of HER2 also makes them eligible for targeted therapies, such as trastuzumab, which specifically attack HER2-positive tumor cells, improving treatment outcomes compared to standard chemotherapy alone.

Get a Free sample for the HER2+ Gastric Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market

HER2+ Gastric Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

HER2+ Gastric Cancer Epidemiology Segmentation:

The HER2+ Gastric Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of HER2+ Gastric Cancer

• Prevalent Cases of HER2+ Gastric Cancer by severity

• Gender-specific Prevalence of HER2+ Gastric Cancer

• Diagnosed Cases of Episodic and Chronic HER2+ Gastric Cancer

Download the report to understand which factors are driving HER2+ Gastric Cancer epidemiology trends @ HER2+ Gastric Cancer Epidemiology Forecast

HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Gastric Cancer market or expected to get launched during the study period. The analysis covers HER2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the HER2+ Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HER2+ Gastric Cancer Therapies and Key Companies

• KEYTRUDA (pembrolizumab): Merck

• ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca

• ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks

• HLX22 (AC101): Shanghai Henlius Biotech and AbClon

• Rilvegostomig: AstraZeneca

• Evorpacept (ALX148): ALX Oncology

• TUKYSA (tucatinib): Pfizer

• BAY2927088: Bayer

• AB-201 (GCC2003,HER2 CAR-NK): Artiva Biotherapeutics and GC Cell

• A166 (Trastuzumab botidotin): KLUS Pharma

• MRG002: Shanghai Miracogen

• AIDIXI (disitamab vedotin): Pfizer

• BAY2701439: Bayer

• ELVN-002: Enliven Therapeutics

• ARX788: Ambrx and NovoCodex

• XMT-2056: Mersana Therapeutics and GSK

• BL-M07D1: SystImmune

Discover more about therapies set to grab major HER2+ Gastric Cancer market share @ HER2+ Gastric Cancer Treatment Landscape

HER2+ Gastric Cancer Market Drivers

• Increasing prevalence of advanced and metastatic gastric and gastroesophageal junction (GEJ) cancers.

• Rising adoption of HER2-targeted therapies such as ENHERTU, HERCEPTIN, and KEYTRUDA.

• Advances in diagnostic testing for HER2 status, enabling personalized treatment approaches.

• Growing awareness among healthcare providers about precision medicine and biomarker-driven therapies.

• Supportive regulatory pathways and accelerated approvals for novel HER2-targeted therapies.

HER2+ Gastric Cancer Market Barriers

• Limited patient population, as only a subset of gastric and GEJ cancers are HER2-positive.

• High cost of targeted therapies, restricting access in low- and middle-income regions.

• Resistance development and limited efficacy in some patients, requiring combination therapies.

• Stringent regulatory requirements and long approval timelines in certain regions.

• Lack of awareness and diagnostic infrastructure in emerging markets.

Scope of the HER2+ Gastric Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key HER2+ Gastric Cancer Companies: Merck, Daiichi Sankyo and AstraZeneca, Jazz Pharmaceuticals, BeiGene, and Zymeworks, Shanghai Henlius Biotech and AbClon, AstraZeneca, ALX Oncology, Pfizer, Bayer, Artiva Biotherapeutics and GC Cell, KLUS Pharma, Shanghai Miracogen, Enliven Therapeutics, Ambrx and NovoCodex, Mersana Therapeutics and GSK, SystImmune, and others

• Key HER2+ Gastric Cancer Therapies: KEYTRUDA (pembrolizumab), ENHERTU (trastuzumab deruxtecan), ZIIHERA (zanidatamab), HLX22 (AC101), Rilvegostomig, Evorpacept (ALX148), TUKYSA (tucatinib), AY2927088, AB-201 (GCC2003,HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others

• HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and HER2+ Gastric Cancer emerging therapies

• HER2+ Gastric Cancer Market Dynamics: HER2+ Gastric Cancer market drivers and HER2+ Gastric Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• HER2+ Gastric Cancer Unmet Needs, KOL’s views, Analyst’s views, HER2+ Gastric Cancer Market Access and Reimbursement

To know more about HER2+ Gastric Cancer companies working in the treatment market, visit @ HER2+ Gastric Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. HER2+ Gastric Cancer Market Report Introduction

2. Executive Summary for HER2+ Gastric Cancer

3. SWOT analysis of HER2+ Gastric Cancer

4. HER2+ Gastric Cancer Patient Share (%) Overview at a Glance

5. HER2+ Gastric Cancer Market Overview at a Glance

6. HER2+ Gastric Cancer Disease Background and Overview

7. HER2+ Gastric Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of HER2+ Gastric Cancer

9. HER2+ Gastric Cancer Current Treatment and Medical Practices

10. HER2+ Gastric Cancer Unmet Needs

11. HER2+ Gastric Cancer Emerging Therapies

12. HER2+ Gastric Cancer Market Outlook

13. Country-Wise HER2+ Gastric Cancer Market Analysis (2020–2034)

14. HER2+ Gastric Cancer Market Access and Reimbursement of Therapies

15. HER2+ Gastric Cancer Market Drivers

16. HER2+ Gastric Cancer Market Barriers

17. HER2+ Gastric Cancer Appendix

18. HER2+ Gastric Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/